You are viewing a javascript disabled version of the site. Please enable Javascript for this site to function properly.
Go to headerGo to navigationGo to searchGo to contentsGo to footer
In content section. Select this link to jump to navigation

131I-chTNT injection to relieve tracheal obstruction in advanced NSCLC patient

Abstract

OBJECTIVE:

To relieve large airway obstruction in a patient with advanced non-small cell lung cancer (NSCLC) by injecting the mouse-human chimeric monoclonal antibody radiolabeled with iodine 131 chimeric tumor necrotic treatment (131I-chTNT) and to study the irradiation absorption in the tumor and critical organs.

METHODS:

A 50-year-old patient with NSCLC was treated with radioimmunotherapy. His airway was still obstructed in spite of intensive chemotherapy and radiotherapy.131I-chTNT was injected into the tumor at the right bronchus through a fiberscope. A131I scan was performed during treatment, and a computed tomography (CT) scan of the chest and fiberscope were performed pre- and post-treatment.131I-chTNT distribution in tissues was followed for up to 4 weeks using gamma camera imaging.

RESULTS:

The radiation material accumulated notably in the tumor, relieving the patient's symptoms by suppressing the tumor. Recanalization of the airway was achieved so that the patient was able to breathe easily and cough.

CONCLUSION:

As a new type of radioimmunotherapy,131I-chTNT may be helpful in treatment of advanced lung cancer.

References

[1] 

Ricke J, , Wust P, , Hengst S, CT-guided interstitial brachytherapy of lung malignancies. Technique and first results. Radiologe. 2004 July; 44(7): 684-686.

[2] 

Ricke J, , Wust P, , Wieners G, CT-guided interstitial single-fraction brachytherapy of lung tumors: phase I results of a novel technique. Chest. 2005 Jun; 127(6): 2237-2242.

[3] 

Wang ZM, , Lu J, , Liu T, CT-guided interstitial brachytherapy of inoperable non-small cell lung cancer. Lung Cancer. 2011; 74(2): 253-257.

[4] 

Sharma Daya Nand, , Rath Goura Kisor, , Thulkar Sanjay, Computerized tomography-guided percutaneous high-dose-rate interstitial brachytherapy for malignant lung lesions. J Cancer Res Ther. 2011; 7(2): 174-179.

[5] 

Wang H, , Cao C, , Li B, Immunogenicity of Iodine 131 chimeric tumor necrosis therapy monoclonal antibody in advanced lung cancer patients. Cancer Immunol Immunother. 2008; 57(5): 677-684. Epub 2007 Oct 13.

[6] 

Chen S, , Yu L, , Jiang C, Pivotal study of iodine-131-radiolabelled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer. J Clin Oncol. 2005; 23(7): 1538-1547.

[7] 

Yu L, , Ju DW, , Chen W, 131I-chTNT radioimmunotherapy of 43 patients with advanced lung cancer. Cancer Biother Radiopharm. 2006; 21(1): 5-14.

[8] 

Laitinen JO, , Tenhumen M, , Kairemo KJ, Absorbed dose estimates for131I-labelled monoclonal antibody therapy in patients with intraperitoneal pseudomyxoma. Nucl Med Commum. 2000; 21(4): 335-360.

[9] 

Denardo SJ, , Williams Le, , Leigh Br, et al. Choosing an Optimal Radioimmunotherapy Dose for Clinical Response. Cancer. 2002; 94(4): 1275-1286.

[10] 

Yu L, , Ju DW, , Chen W, et al. 131I-chTNT radioimmunotherapy of 43 patients with advanced lung cancer [J]. Cancer Biother Radiopharm. 2006; 21(1): 5-14.

[11] 

Niu Lizhi, , Zhou Liang, , Xu Kecheng, Combination of cryosurgery and Iodine-125 seeds brachytherapy for lung cancer. J Thorac Dis. 2012; 4(5): 504-507.